These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 31999044)

  • 1. Improvement in Quality of Life and Decrease in Large-Volume Paracentesis Requirements With the Automated Low-Flow Ascites Pump.
    Wong F; Bendel E; Sniderman K; Frederick T; Haskal ZJ; Sanyal A; Asrani SK; Capel J; Kamath PS
    Liver Transpl; 2020 May; 26(5):651-661. PubMed ID: 31999044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transjugular intrahepatic portosystemic shunt and alfapump® system for refractory ascites in liver cirrhosis: Outcomes and complications.
    Will V; Rodrigues SG; Stirnimann G; Gottardi A; Bosch J; Berzigotti A
    United European Gastroenterol J; 2020 Oct; 8(8):961-969. PubMed ID: 32588789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alfapump® system vs. large volume paracentesis for refractory ascites: A multicenter randomized controlled study.
    Bureau C; Adebayo D; Chalret de Rieu M; Elkrief L; Valla D; Peck-Radosavljevic M; McCune A; Vargas V; Simon-Talero M; Cordoba J; Angeli P; Rosi S; MacDonald S; Malago M; Stepanova M; Younossi ZM; Trepte C; Watson R; Borisenko O; Sun S; Inhaber N; Jalan R
    J Hepatol; 2017 Nov; 67(5):940-949. PubMed ID: 28645737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of refractory ascites with an automated low-flow ascites pump in patients with cirrhosis.
    Stirnimann G; Berg T; Spahr L; Zeuzem S; McPherson S; Lammert F; Storni F; Banz V; Babatz J; Vargas V; Geier A; Stallmach A; Engelmann C; Trepte C; Capel J; De Gottardi A
    Aliment Pharmacol Ther; 2017 Nov; 46(10):981-991. PubMed ID: 28940225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients with refractory ascites treated with alfapump® system have better health-related quality of life as compared to those treated with large volume paracentesis: the results of a multicenter randomized controlled study.
    Stepanova M; Nader F; Bureau C; Adebayo D; Elkrief L; Valla D; Peck-Radosavljevic M; McCune A; Vargas V; Simon-Talero M; Cordoba J; Angeli P; Rossi S; MacDonald S; Capel J; Jalan R; Younossi ZM
    Qual Life Res; 2018 Jun; 27(6):1513-1520. PubMed ID: 29460201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Final safety and efficacy results from a 106 real-world patients registry with an ascites-mobilizing pump.
    Stirnimann G; Berg T; Spahr L; Zeuzem S; McPherson S; Lammert F; Storni F; Banz V; Babatz J; Vargas V; Geier A; Engelmann C; Herber A; Trepte C; Capel J; De Gottardi A
    Liver Int; 2022 Oct; 42(10):2247-2259. PubMed ID: 35686702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Automated low flow pump system for the treatment of refractory ascites: a single-center experience.
    Thomas MN; Sauter GH; Gerbes AL; Stangl M; Schiergens TS; Angele M; Werner J; Guba M
    Langenbecks Arch Surg; 2015 Dec; 400(8):979-83. PubMed ID: 26566989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transjugular Intrahepatic Portosystemic Shunts With Covered Stents Increase Transplant-Free Survival of Patients With Cirrhosis and Recurrent Ascites.
    Bureau C; Thabut D; Oberti F; Dharancy S; Carbonell N; Bouvier A; Mathurin P; Otal P; Cabarrou P; Péron JM; Vinel JP
    Gastroenterology; 2017 Jan; 152(1):157-163. PubMed ID: 27663604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An update on the pathogenesis and clinical management of cirrhosis with refractory ascites.
    Neong SF; Adebayo D; Wong F
    Expert Rev Gastroenterol Hepatol; 2019 Apr; 13(4):293-305. PubMed ID: 30791777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current treatment options of refractory ascites in liver cirrhosis - A systematic review and meta-analysis.
    Will V; Rodrigues SG; Berzigotti A
    Dig Liver Dis; 2022 Aug; 54(8):1007-1014. PubMed ID: 35016859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Management of refractory ascites by the automated low flow pump system (Alfapump)].
    Restellini S; Soares PC; Giostra E; Spahr L
    Rev Med Suisse; 2014 Sep; 10(440):1607-8, 1610-1. PubMed ID: 25276999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ePTFE-TIPS vs repetitive LVP plus albumin for the treatment of refractory ascites in patients with cirrhosis.
    Bucsics T; Hoffman S; Grünberger J; Schoder M; Matzek W; Stadlmann A; Mandorfer M; Schwabl P; Ferlitsch A; Peck-Radosavljevic M; Trauner M; Karner J; Karnel F; Reiberger T
    Liver Int; 2018 Jun; 38(6):1036-1044. PubMed ID: 29091351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Automated low-flow ascites pump in a real-world setting: complications and outcomes.
    Solbach P; Höner Zu Siederdissen C; Wellhöner F; Richter N; Heidrich B; Lenzen H; Kerstin P; Hueper K; Manns MP; Wedemeyer H; Jaeckel E
    Eur J Gastroenterol Hepatol; 2018 Sep; 30(9):1082-1089. PubMed ID: 29738325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites.
    Rössle M; Ochs A; Gülberg V; Siegerstetter V; Holl J; Deibert P; Olschewski M; Reiser M; Gerbes AL
    N Engl J Med; 2000 Jun; 342(23):1701-7. PubMed ID: 10841872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of refractory ascites.
    Wong F
    Clin Mol Hepatol; 2023 Jan; 29(1):16-32. PubMed ID: 35676862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis.
    Ginès P; Uriz J; Calahorra B; Garcia-Tsao G; Kamath PS; Del Arbol LR; Planas R; Bosch J; Arroyo V; Rodés J
    Gastroenterology; 2002 Dec; 123(6):1839-47. PubMed ID: 12454841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment for ascites in adults with decompensated liver cirrhosis: a network meta-analysis.
    Benmassaoud A; Freeman SC; Roccarina D; Plaz Torres MC; Sutton AJ; Cooper NJ; Iogna Prat L; Cowlin M; Milne EJ; Hawkins N; Davidson BR; Pavlov CS; Thorburn D; Tsochatzis E; Gurusamy KS
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD013123. PubMed ID: 31978257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness of Transjugular Intrahepatic Portosystemic Shunt versus Large-Volume Paracentesis in Refractory Ascites: Results of a Markov Model Incorporating Individual Patient-Level Meta-Analysis and Nationally Representative Cost Data.
    Kwan SW; Allison SK; Gold LS; Shin DS
    J Vasc Interv Radiol; 2018 Dec; 29(12):1705-1712. PubMed ID: 30392803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current management of refractory ascites in patients with cirrhosis.
    Zhao R; Lu J; Shi Y; Zhao H; Xu K; Sheng J
    J Int Med Res; 2018 Mar; 46(3):1138-1145. PubMed ID: 29210304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First reports of clinical effects of transjugular intrahepatic portosystemic shunt in four patients with cirrhotic ascites refractory to tolvaptan.
    Tsuruya K; Koizumi J; Sekiguchi Y; Ono S; Sekiguchi T; Hara T; Mishima Y; Arase Y; Hirose S; Shiraishi K; Kagawa T
    BMJ Open Gastroenterol; 2023 Apr; 10(1):. PubMed ID: 37085275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.